Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Infigratinib for Achondroplasia
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial studies the long-term safety, tolerability, and efficacy of a drug to treat ACH, and also assesses the quality of life of those affected.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service